Study populationa | Practice populationb | ||||||
---|---|---|---|---|---|---|---|
Outcome measure | Baseline | 6-month n/N (%) | P-value | 12-month n/N (%) | P-valuec | 6-month n/N (%) | 12-month n/N (%) |
Primary outcome: high-risk prescribing | 70/870 (8.0) | 47/807 (5.8); 52/870 (6.0) LVCF | 0.030.04 | 62/757 (8.2); 74/870 (8.5) LVCF | 0.90.7 | 71/890 (8.0) | 101/1026 (9.8) |
Secondary outcomes | |||||||
High-risk prescribing among patients with any gastrointestinal risk factor | 35/649 (5.4) | 26/596 (4.4); 29/649 (4.5) LVCF | 0.40.4 | 33/554 (6.0); 42/649 (6.5) LVCF | 0.60.4 | 39/698 (5.6) | 52/731 (7.1) |
High-risk prescribing amongst patients with any renal risk factor | 41/476d (8.6) | 22/444 (5.0); 25/476 (5.3) LVCF | 0.0070.008 | 33/414 (8.0); 38/476 (8.0) LVCF | 0.70.7 | 38/365 (10.4) | 61/536 (11.4) |
High-risk prescribing among patients with congestive heart failure | 1/27 (3.7) | 1/23 (4.4); 1/27 (3.7) LVCF | 0.91.0 | 1/21 (4.8); 1/27 (3.7) LVCF | 0.91.0 | 1/26 (3.9) | 1/25 (4.0) |
aPatients vulnerable at baseline; that is at increased risk of adverse drug events (ADE) when prescribed NSAID and/or antiplatelet medicines (see Table 1). bAll practice vulnerable patients; that is includes patients who were not vulnerable at baseline but who have become so at 6 months and/or 12 months. cCompared with baseline.d32/870 (3.7%) patients were included as at-risk of ADE due to a low eGFR, where it could not be confirmed that the latest eGFR was still <60. LVCF = last value carried forward, which assumes that those lost to follow-up (left the practice or died) had the same high-risk prescribing status as baseline.